The focus of our research has been the development of new therapy for inherited disorders of metabolism, especially glycogen storage disease (GSD) and phenylketonuria (PKU). GSD results from the deficiency of specific enzymes involved in the storage and retrieval of glucose in the body: glucose-6-phosphatase (G6Pase) in GSD type Ia and acid -glucosidase (GAA) in GSD type II (Pompe disease).
1) GSD type Ia: G6Pase-knockout mice provided a model for the biochemical abnormalities of GSD type Ia, although early mortality complicates research with both the murine and canine models of GSD type Ia.
2) GSD type II/Pompe disease: Pompe disease is characterized by the massive accumulation of lysosomal glycogen in striated muscle with an accompanying disruption of cellular functions.
3) PKU: We demonstrated long-term biochemical correction of PKU in mice with an AAV2 vector.